TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
Authors:
Open Access
- 15 January 2021
- journal article
- research article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 53 (1) , 9-24
Abstract
PurposeTo find biomarkers for disease, there have been constant attempts to investigate the genes that differ from those in the disease groups. However, the values that lie outside the overall pattern of a distribution, the outliers, are frequently excluded in traditional analytical methods as they are considered to be ‘some sort of problem.’ Such outliers may have a biologic role in the disease group. Thus, this study explored new biomarker using outlier analysis, and verified the suitability of therapeutic potential of two genes (TM4SF4 and LRRK2).Materials and MethodsModified Tukey’s fences outlier analysis was carried out to identify new biomarkers using the public gene expression datasets. And we verified the presence of the selected biomarkers in other clinical samples via customized gene expression panels and tissue microarrays. Moreover, a siRNA-based knockdown test was performed to evaluate the impact of the biomarkers on oncogenic phenotypes.ResultsTM4SF4 in lung cancer and LRRK2 in breast cancer were chosen as candidates among the genes derived from the analysis. TM4SF4 and LRRK2 were overexpressed in the small number of samples with lung cancer (4.20%) and breast cancer (2.42%), respectively. Knockdown of TM4SF4 and LRRK2 suppressed the growth of lung and breast cancer cell lines. The LRRK2 overexpressing cell lines were more sensitive to LRRK2-IN-1 than the LRRK2 under-expressing cell linesConclusionOur modified outlier-based analysis method has proved to rescue biomarkers previously missed or unnoticed by traditional analysis showing TM4SF4 and LRRK2 are novel target candidates for lung and breast cancer, respectively.Keywords
Funding Information
- National Research Foundation of Korea (2015H1A2A1034732, 2016R1A5A2945889, 2019R1A2B5B02069979)
This publication has 29 references indexed in Scilit:
- Targeting RET-rearranged non-small-cell lung cancer: future prospectsLung Cancer: Targets and Therapy, 2019
- Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challengesMolecular Cancer, 2018
- Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast CancerMolecular Cancer Therapeutics, 2018
- Molecular Testing of Lung CancersJournal of Pathology and Translational Medicine, 2017
- Drug-biomarker co-development in oncology – 20 years and countingDrug Resistance Updates, 2017
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targetsNature Communications, 2015
- The L6 domain tetraspanin Tm4sf4 regulates endocrine pancreas differentiation and directed cell migrationDevelopment, 2011
- Elevated expression of CDK4 in lung cancerJournal of Translational Medicine, 2011
- COPA—cancer outlier profile analysisBioinformatics, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005